The companies have an expansive clinical program for the mRNA neoantigen therapy intismeran autogene in combination with ...
Moderna’s experimental mRNA-based flu vaccine demonstrated a stronger immune response than a currently available standard flu shot in a late-stage phase 3 trial, clearing a path for regulatory ...
At the time of this analysis, the Braftovi combination regimen with FOLFIRI and cetuximab demonstrated a clinically meaningful and statistically significant improvement in confirmed objective response ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results